Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.